UAE activates new system to end monopoly on medical products

The Emirates Drug Establishment (EDE) has activated a new mechanism aimed at ending monopolies on medical products in the UAE.

It requires pharmaceutical companies to appoint more than one authorised agent for each medical product marketed in the country.

The move, introduced under the 2024 federal law governing medical products, pharmacists and pharmaceutical establishments, is designed to strengthen pharmaceutical security, ensure steady supplies and improve national readiness during emergencies.

It will also make the market more attractive for investment, widen treatment options and boost competition among distributors.

Officials say the mechanism will enhance supply‑chain flexibility, improve distribution efficiency and prevent monopolistic practices.

Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the EDE's Board of Directors, said the initiative reflects the UAE’s broader public policy approach to building a resilient national pharmaceutical ecosystem.

He stressed the authority’s commitment to diversifying supply chains, enhancing regulatory efficiency and creating a flexible legislative environment that supports market sustainability and protects public health.

As part of the activation of the new mechanism to break the monopoly of medical products, H.E Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, stated that this regulatory step enhances supply management efficiency and pic.twitter.com/4NtysINUkW

— Emirates Drug Establishment مؤسسة الإمارات للدواء (@EDE_UAE) February 24, 2026